Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

By R. Brentjens, I. Rivière, Jae H. Park, M. Davila, Xiuyan Wang, J. Stefanski, Clare Taylor, Raymond Yeh, S. Bartido, Oriana Bórquez-Ojeda and 17 more. Blood, 2011

1,290 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/50c0ac9425bf9cec792d8489a4de9c3decbd93e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Immunology

In Oncology

Citations in the corpus

Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “Diarrhea, colitis, nausea, and abdominal pain have been reported following CD19 CAR T-cell infusions.(4,10,12,14,16)”
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “The addition of lymphodepletion chemotherapy has been anecdotally shown to increase persistence of CAR T cells [63].”
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015, neutral): “Comparing efficacy and toxicity outcomes in different studies is difficult because of patient heterogeneity and differences in vector design, culture methods, and cell doses 3–10,35,44 .”
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016, background): “, 2015) appears superior to that of CD28 domains (Brentjens et al., 2011).”
Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) (2014, background): “2011 Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias BLOOD [61]”
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013, background): “Early clinical results have demonstrated impressive antitumor effects in patients with leukemia (6-10), although the ideal CAR design with respect to structural and signaling features remains unclear and has been the topic of intense inquiry.”
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013, neutral): “Her baseline karyotype was 46,XX,del(1)(p13),t(2;9)(q?21;q?21), t(3;17)(p24;q23),del(6)(q16q21),del(9)(q13q22), der(16)t(1;?;16)(p13;?p13.”
Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015, neutral): “Under stringent experimental conditions, we studied their relative potency in a xenogeneic model of ALL.”
Gene therapy comes of age (2018, positive): “CAR-T cells have had a large impact on the treatment of certain cancers (139), and this success provides a foundation for future T cell–based therapies for other cancers and other diseases such as autoimmune disorders and AIDS (5, 140).”